CA2558067A1 — Novel benzoxazinone derivatives used as long-acting betamimetics for treating respiratory illnesses
Assigned to Boehringer Ingelheim International GmbH · Expires 2005-10-06 · 21y expired
What this patent protects
Benzoxazinone derivatives (I) are new. Benzoxazinone derivatives of formula (I) and their isomers and acid addition salts are new. n : 1 or 2; A : O or a bond; R : 1-6C alkyl or haloalkyl; R 1>-R 3>H, Q 1>, 1-6C haloalkyl, OH, Q 2>OH, OQ 1>, 6-10C aryl, (6-10C)aryl…
USPTO Abstract
Benzoxazinone derivatives (I) are new. Benzoxazinone derivatives of formula (I) and their isomers and acid addition salts are new. n : 1 or 2; A : O or a bond; R : 1-6C alkyl or haloalkyl; R 1>-R 3>H, Q 1>, 1-6C haloalkyl, OH, Q 2>OH, OQ 1>, 6-10C aryl, (6-10C)aryl(1-4C)alkyl, (6-10C)aryl(1-6C)alkoxy, COOH, COOQ 1>, OQ 2>COOH, OQ 2>COOQ 1>, NHSO 3H, NHSO 2Q 1>, NH 2, NHQ 1>, N(Q 1>) 2, NO 2, SQ 1>, SO 2Q 1>, SOQ 1>, OCOQ 1>, COQ 1>, NHCOQ 1> or halo; Q 1>1-6C alkyl; Q 2>1-6C alkylene. [Image] ACTIVITY : Antiinflammatory; Antiasthmatic. No biological data given. MECHANISM OF ACTION : Beta mimetic.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.